University Of Erlangen Nuremberg is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
University Of Erlangen Nuremberg is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The University of Erlangen-Nuremberg (Friedrich-Alexander-Universität Erlangen-Nürnberg, FAU) is one of Germany's leading research universities. Located in Erlangen and Nuremberg, Bavaria, it has particular strength in medicine, life sciences, and engineering. The university hosts the FAU Medical Center and numerous neuroscience research institutes. [@fau2024]
| | | [@german]
|---|---| [@center2024]
| Name | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| Location | Erlangen, Nuremberg, Bavaria, Germany |
| Type | Public Research University |
| Founded | 1742 |
| Students | ~40,000 |
| Website | https://www.fau.eu |
FAU was founded in 1742 by Frederick, Margrave of Brandenburg-Bayreuth, making it one of Germany's oldest universities. Over its 280-year history, FAU has evolved from a small theological seminary into one of the country's largest and most research-intensive universities. The university has a particular tradition in medicine and natural sciences.
FAU operates across multiple campuses:
| Center | Focus | Notable Work |
|--------|-------|---------------|
| Neurology Department | AD, PD, ALS, MS | Clinical trials, biomarker studies |
| Interdisciplinary Center for Bioinformatics | Bioinformatics | Genomics, proteomics, AI |
| Center for Rare Diseases | Rare neuro conditions | Gene discovery, novel therapies |
| Center for Protein Biotechnology | Protein aggregation | Drug discovery, structural biology |
| Institute of Biochemistry | Enzyme mechanisms | Drug targets, therapeutic development |
FAU researchers have made significant contributions to neurodegenerative disease research:
| Disease | Research Priority |
|---------|------------------|
| Alzheimer's Disease | Biomarkers, clinical trials, neuroinflammation |
| Parkinson's Disease | Alpha-synuclein, LRRK2, mitochondria |
| ALS | Genetics, therapy development |
| Prion Diseases | Mechanisms, diagnostics |
| Multiple Sclerosis | Autoimmunity, remyelination |
FAU maintains extensive international partnerships:
FAU provides state-of-the-art research infrastructure:
Imaging Center:
FAU maintains important research databases:
FAU receives substantial neurodegeneration research funding:
| Source | Annual Amount (EUR) | Focus |
|--------|---------------------|-------|
| DZNE Core | 6M | Basic/translational |
| EU Grants | 4M | Collaborative projects |
| BMBF | 5M | German research programs |
| Industry | 5M | Clinical trials |
| Foundations | 2M | Training, pilot projects |
Recent major grants:
| Researcher | Position | Focus |
|------------|----------|-------|
| Prof. Jürgen Winkler | Dept. of Neurology Chair | AD, biomarkers |
| Prof. Jochen Herms | Neurobiology | Tau, amyloid |
| Prof. Christian Blank | Movement Disorders | PD, DBS |
| Prof. Thomas Gasser | Neurogenetics | PD genetics |
| Prof. Martin Bendszus | Neuroradiology | Imaging biomarkers |
The university offers comprehensive training:
The International Max Planck Research School offers:
The university hospital provides comprehensive neurological care:
FAU produces significant research output:
FAU operates within the broader German neurodegeneration research ecosystem, which represents one of the most coordinated national efforts to understand and treat neurodegenerative diseases globally. Germany hosts the German Center for Neurodegenerative Diseases (DZNE), a nationwide research consortium with ten sites across the country. FAU serves as one of the founding partner institutions of this initiative, contributing both basic science expertise and clinical research infrastructure to the collective effort[@kornhuber2020].
The German research landscape distinguishes itself through its integration of academic medical centers, Max Planck Institutes, and university hospitals into collaborative networks. This structure enablesFAU researchers to access complementary expertise in structural biology, computational neuroscience, and clinical neurology. The DZNE operates under the Helmholtz Association, Germany's largest research organization, providing substantial and sustained funding for long-term research programs[@herms2020].
FAU's participation in the DZNE enables access to the German Dementia Registry (GDR), a nationwide database that aggregates clinical, genetic, and biomarker data from over 15,000 research participants across Germany. This registry supports longitudinal studies on disease progression, genetic risk factor identification, and biomarker validation. FAU contributes data from its memory clinic cohort and participates in cross-site analyses that leverage the registry's scale[@blank2021].
The university's strategic position in Bavaria also connects it to the European Union's Horizon Europe research funding framework. FAU leads or participates in multiple multinational consortia focused on neurodegeneration, including projects examining protein aggregation mechanisms, neuroinflammation signaling pathways, and novel therapeutic target validation. These European collaborations provide access to patient cohorts spanning multiple countries and enable clinical trial recruitment across borders[gasser2018].
FAU Medical Center maintains one of Germany's most active neurodegeneration clinical trial portfolios, with over 40 ongoing studies across Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. The trials span the full development pipeline from first-in-human safety studies to large Phase III efficacy trials[bendszus2022].
Alzheimer's Disease Trials:
The Alzheimer's program includes participation in global amyloid-targeting immunotherapy trials, tau aggregation inhibitors, and neuroprotection studies. FAU serves as a primary European recruitment site for several major trials, leveraging its memory clinic infrastructure and established patient registry. The center also conducts investigator-initiated trials examining repurposed drugs including metformin, GLP-1 receptor agonists, and standard anti-inflammatory agents[hauser2021].
Parkinson's Disease Trials:
The movement disorders program focuses on disease-modifying therapies targeting alpha-synuclein aggregation, LRRK2 kinase inhibition, and mitochondrial protection. FAU participates in the Michael J. Fox Foundation's Parkinson's Progression Markers Initiative (PPMI) as a German study site, contributing longitudinal clinical, genetic, and biomarker data to this landmark observational study[saft2022].
ALS Clinical Trials:
FAU contributes to the German ALS Registry and participates in international clinical trials for ALS therapeutics. The program emphasizes genetic characterization of ALS patients, with particular focus on C9orf72 repeat expansions and their phenotypic correlates. Investigator-initiated studies examine neuroinflammatory biomarkers and their relationship to disease progression[otto2021].
The Clinical Trials Unit at FAU maintains:
Led by Prof. Jochen Herms, this group focuses on the cellular and molecular mechanisms underlying tau pathology in Alzheimer's disease and related tauopathies. Current research programs examine tau seeding and aggregation, the role of microglia in tau propagation, and the development of tau-targeted immunotherapeutics. The group employs molecular biology, cellular imaging, and mouse model approaches to understand how tau pathology spreads through neural circuits and contributes to cognitive decline[@herms2020].
Prof. Jürgen Winkler's laboratory investigates the role of neuroinflammation in neurodegenerative diseases, with particular emphasis on the contributions of innate immune cells to disease progression. Research programs examine cytokine signaling in Alzheimer's disease, the role of the NLRP3 inflammasome in neurodegeneration, and the development of anti-inflammatory therapeutic approaches. The laboratory has established human iPSC-derived microglial models to study neuroinflammatory mechanisms in patient-specific contexts[winkler2019].
Prof. Christian Blank leads the movement disorders group, which conducts both basic and clinical research on Parkinson's disease and related disorders. Basic science programs examine alpha-synuclein aggregation mechanisms and LRRK2 biology, while clinical research focuses on deep brain stimulation optimization, wearable sensor development for motor monitoring, and clinical trial leadership for disease-modifying therapies[blank2021].
The Clinical Trials Unit coordinates all industry-sponsored and investigator-initiated clinical trials across neurodegenerative disease indications. The unit maintains specialized expertise in:
Prof. Martin Bendszus leads the neuroimaging program, which develops and applies advanced MRI and PET techniques for neurodegenerative disease diagnosis and monitoring. Research programs include arterial spin labeling perfusion imaging, diffusion tensor imaging for white matter integrity assessment, and amyloid/tau PET quantification methods. The group collaborates with the German Center for Neurodegenerative Diseases to establish imaging biomarkers as endpoints in clinical trials[bendszus2022].
The proteomics facility provides mass spectrometry-based protein analysis for all FAU neuroscience research groups. Services include:
FAU provides comprehensive training pathways for students and postdocs interested in neurodegeneration research. The International Max Planck Research School (IMPRS) for Molecular Science offers a four-year doctoral program with rotation through multiple laboratories before thesis selection. The program admits approximately 20 students annually and provides full stipend support[stangel2023].
The neuroscience graduate program includes coursework in cellular and molecular neuroscience, systems neuroscience, and clinical neurology. Students complete rotations through at least three laboratories before selecting a thesis advisor, ensuring broad exposure to different research approaches. Doctoral theses typically require 4-5 years to complete, with graduates proceeding to postdoctoral positions at leading institutions worldwide.
Clinical training programs include neurology residency and subspecialty fellowships in movement disorders, cognitive neurology, and neuroimmunology. The fellowship programs accept both German and international physicians, with clinical training supplemented by research project participation. Several fellows have proceeded to faculty positions following fellowship completion.
FAU Medical Center serves as the primary neurological care provider for the greater Erlangen-Nuremberg metropolitan area, with a catchment population of approximately 2 million people. The memory disorder clinic evaluates over 3,000 new patients annually, while the movement disorders center manages care for more than 5,000 Parkinson's disease patients[ziegler2023].
The university hospital's neurology department operates 150 inpatient beds, including dedicated units for:
FAU has trained numerous researchers who have proceeded to leadership positions in neurodegeneration research worldwide. Notable alumni include:
The neurodegeneration research program at FAU operates with an annual budget exceeding €25 million from competitive grants, industry partnerships, and institutional support. This diversified funding model provides stability while enabling strategic investments in new research directions.
Key funding sources include:
The University of Erlangen-Nuremberg (FAU) represents a major center for neurodegenerative disease research in Germany and Europe. Its integration into the German Center for Neurodegenerative Diseases, combined with strong clinical trial infrastructure and basic science research programs, positions FAU as a leader in understanding disease mechanisms and developing new therapies. The university's strategic location in Bavaria, access to European research networks, and comprehensive training programs ensure continued contributions to the field. FAU researchers have made significant advances in biomarker development, clinical trial execution, and basic mechanism elucidation, with ongoing programs in precision medicine, AI-assisted diagnosis, and novel therapeutic approaches holding promise for continued progress against these devastating diseases.